<?xml version="1.0" encoding="UTF-8"?>
<p>In the last ten years, there has been an increasing incidence of disseminated filamentous fungal infections in patients with severe immunosuppression [
 <xref rid="B1-idr-13-00002" ref-type="bibr">1</xref>,
 <xref rid="B2-idr-13-00002" ref-type="bibr">2</xref>,
 <xref rid="B4-idr-13-00002" ref-type="bibr">4</xref>]. Hematological malignancies have a risk of 6.5% for IFI [
 <xref rid="B5-idr-13-00002" ref-type="bibr">5</xref>], mainly in the induction and consolidation phases. This increase is due to severe immunosuppression conditions by myelotoxic treatments and related clinical conditions but also to new technologies such as molecular biology [
 <xref rid="B6-idr-13-00002" ref-type="bibr">6</xref>,
 <xref rid="B7-idr-13-00002" ref-type="bibr">7</xref>] that have increased the diagnosis ability.
</p>
